Recurrent or Persistent Endometrial Carcinoma
Conditions
Keywords
Endometrial cancer, Recurrent or persistent endometrial carcinoma, Progesterone Receptor Negative, Sodium cridanimod, Virexxa
Brief summary
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer.
Detailed description
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer. Eligible patients will be enrolled into the study and administered sodium cridanimod in combination progestin therapy. Objective responses will be assessed at 12 week intervals. Patients will be treated for a 12 month period, followed by an additional 12 month follow up period or to disease progression whichever occurs first. Important objectives of the study are to investigate the effect of sodium cridanimod in conjunction with progestin therapy on the level of PrR in tumor tissue and how this correlates to efficacy. To accomplish this objective, some of the patients enrolled in the study will undergo two tumor biopsies that will allow measurement of PrR levels in the tumor tissue before the treatment and after 4 weeks of therapy.
Interventions
Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
Sponsors
Pharmasyntez
Kevelt AS
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients age 18 and older; * Histologically confirmed papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required); * Patient has documented evidence of PrR negative endometrial cancer. PrR negativity can be determined by immunohistochemistry. The tumor is considered PrR negative if the number of PrR positive cells is less than 1% determined by immunohistochemistry; * Availability of tumor tissue sample that can be used for assessment of PrR levels with the use of immunohistochemistry; * Recurrent or persistent (after the failure of chemotherapy) disease that cannot be treated with surgery or radiotherapy; * Documented disease progression after a platinum based chemotherapy in patients for whom administration of taxanes and anthracyclines is not planned. Progression must fulfill one of the following criteria: * Progression has occurred within 30 days of platinum based chemotherapy consisting of minimum of two cycles of cisplatin-based (≥60 mg/m2/cycle) or carboplatin-based (≥300 mg/m2/cycle, or area under the time-concentration curve ≥4) chemotherapy. * Progression after neoadjuvant or adjuvant platinum based chemotherapy if the recurrence occurred while on neoadjuvant/adjuvant chemotherapy or within 6 months since the last administration of such therapy. * Measurable disease as defined by RECIST 1.1 criteria; * At least one target lesion to be used to assess response, as defined by RECIST 1.1 criteria; * Tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented; * GOG performance status 0-2; * Glomerular filtration rate ≥ 50 mL/min; * Total bilirubin normal; * AST ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN for patients with liver metastases); * Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases); * Albumin ≥ 3.0 mg/dL; * Ability to take oral medication; * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Evidence of histology of the tumor other than papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma or mixed histology of the tumor; * History of hormonal therapy for endometrial carcinoma for more than 3 months; * History of use of progestins for a period of longer than 3 months for any indication, including endometriosis; * Concurrent maintenance corticosteroids; * Concurrent oral contraceptives/ Fertile patients must use effective barrier contraception; * Pregnancy as determined by pregnancy test or nursing; * History of bleeding (i.e. disseminated intravascular coagulation or clotting factor deficiency); * Prior major surgery less than 4 weeks prior to the start of the study; * Concurrent serious illness which, in the opinion of the investigator, would place the patient at unreasonable risk from study therapy; * Previous malignancy less than 3 years ago other than in situ carcinoma of the cervix, basal cell carcinoma or squamous carcinoma of the skin; * History of allergic reactions or idiosyncrasy attributed to progestins or compounds of similar chemical structure to sodium cridanimod or lidocaine; * Known brain metastases; * Other concurrent investigational agents; * Other concurrent anticancer therapies. * Known carrier of HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival | 24 months |
| Time to response | 12 months |
| Overall survival | 24 months |
| Overall Disease Control Rate | 24 months |
| Time to progression | 24 months |
Other
| Measure | Time frame |
|---|---|
| Progesterone receptor (PrR) levels | 1 months |
Countries
Belarus, Czechia, Slovakia, Ukraine, United States
Outcome results
None listed